Iconovo announces plans for development of inhaled GLP-1 products for the treatment of obesity

DPI developers Iconovo have announced plans to develop inhaled GLP-1 receptor agonists for the treatment of obesity and, potentially, related metabolic diseases. The company says that it plans to conduct preclinical proof-of-concept studies itself and then will look to out-license the inhalers. As part of its efforts in this area, the company said that it had filed “a broad patent application related to inhaled GLP-1 receptor agonists.”

Earlier this year, Iconovo appointed Gary Pitcairn as Senior Scientific Advisor, saying that the hire was meant to support development projects involving the reformulation of APIs, including biologics, for inhalation.

Iconovo CEO Johan Wäborg commented, “As a leading inhalation company, with a range of fully developed inhaler platforms and the competence to formulate pharmaceutical compounds into powders, we are in a perfect position to take a step into reformulation of selected high-value products in areas where inhalation can offer significant patient benefits. We are very excited to take this important step towards the development of a next generation of patient-friendly GLP-1 treatments with sustained efficacy.”

Read the Iconovo press release.